Affect Therapeutics
New York, US · Founded 2020 · Delaware corporation · 162 employees on LinkedIn · 8 known investors
Affect Therapeutics operates an app-based digital treatment provider offering care for substance use disorders (alcohol, cannabis, opioid) and mental health conditions like depression and anxiety, using methods such as contingency management, CBT, medication-assisted treatment, and peer support. It serves members across the U.S. including those covered by Medicaid, and works with providers, courts, employers, and health systems.
Founders & leadership
Affect Therapeutics was founded in 2020 by Jeff DeFlavio.
JD
Jeff DeFlavioinExecutive Chairman and co-FounderCo-founder of Affect Therapeutics, an app-based digital treatment provider offering care for substance use disorders and mental health conditions across the U.S.
KM
Kristin MuhlnerinChief Executive Officer
Board
KR
Kevin RyanBoard director
JR
Investors · 8
Artis Ventures✓ verifiedSan Francisco · $50K – $25M
City Light✓ verifiedNew York · $1M – $6M
AlleyCorp✓ verifiedNew York · $1M – $5M
LifeArc VenturesLondon
Samsung NextSan Jose · $100K – $5M
What If VenturesFriscovia Stephen Hays · inferred
Allumia VenturesreportedSeattle · $5M – $15M
Also in the syndicate · 1
CityLight
Funding
SEC filings, press & company announcements$24.6M disclosed across 2 of 3 rounds · 2021–2025
- Undisclosed amountSeries BNov 2025
Allumia Ventures (lead)
Source ↗
▶$18.1MraisedJul 2023 · 9 investors · Other Health CareRule 506(b)
▶$18.1MraisedJul 2023 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jeff RinehartDirector
- Kevin RyanDirector
- Jeff DeFlavioDirector
- Stuart PetersonDirector
- Kristin MuhlnerExecutive Officer, Director
- Offering amount
- $18.1M
- Amount sold
- $18.1M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$6.5MraisedSep 2021 · 10 investors · OtherRule 506(b)
▶$6.5MraisedSep 2021 · 10 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Kevin RyanDirector
- Kristin MuhlnerExecutive Officer, Director
- Jeff RinehartDirector
- Jeff DeFlavioDirector
- Offering amount
- $6.5M
- Amount sold
- $6.5M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Bicycle Health91 shared keywordsBicycle Health provides treatment and support for opioid use disorder (OUD). The company specializes in addressing substance use disorders through clinical care programs.
Klinic87 shared keywordsHealthcare company that raised a $24M Series A
Ophelia83 shared keywordsOphelia provides medication-assisted treatment for opioid addiction through a telemedicine platform, allowing patients to receive care without attending residential rehab. The service is designed for individuals struggling with opioid addiction who prefer privacy-respecting, home-based treatment options.
ReVIDA Recovery Centers75 shared keywordsReVIDA Recovery operates a network of outpatient recovery centers that treat opioid use disorder using Medication Assisted Treatment (MAT) and a multi-disciplinary behavioral healthcare approach. It serves patients across Middle and Eastern Tennessee and Southwest Virginia, with a focus on the Appalachia region.
Eleanor Health65 shared keywordsEleanor Health is an outpatient addiction treatment program that delivers remote evidence-based care for substance use disorder, including medication-assisted treatment and counseling. The service addresses underlying trauma and behavioral health conditions alongside addiction through online consultations with addiction counselors and peer recovery specialists.
Companies competing with Affect Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $309.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Affect Therapeutics do?
- Affect Therapeutics operates an app-based digital treatment provider offering care for substance use disorders (alcohol, cannabis, opioid) and mental health conditions like depression and anxiety, using methods such as contingency management, CBT, medication-assisted treatment, and peer support. It serves members across the U.S. including those covered by Medicaid, and works with providers, courts, employers, and health systems.
- Who founded Affect Therapeutics?
- Affect Therapeutics was founded by Jeff DeFlavio in 2020.
- Who are Affect Therapeutics's investors?
- Affect Therapeutics's investors include Artis Ventures, City Light, AlleyCorp, LifeArc Ventures, Samsung Next, What If Ventures, Allumia Ventures.
- How much funding has Affect Therapeutics raised?
- Affect Therapeutics has disclosed $24.6M raised across 2 of its 3 known rounds.
- Where is Affect Therapeutics headquartered?
- Affect Therapeutics is headquartered in New York, US.